title: Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
abstract: BACKGROUND
  Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low-potency antipsychotic drugs are often perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects. This review examined the effects of the high-potency antipsychotic fluphenazine compared to those of low-potency antipsychotics.
  
  
  OBJECTIVE
  To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia.
  
  
  METHODS
  We searched the Cochrane Schizophrenia Group Trials Register (November 2010).
  
  
  METHODS
  We included all randomised controlled trials (RCTs) comparing fluphenazine with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.
  
  
  METHODS
  We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model.
  
  
  RESULTS
  The review currently includes seven randomised trials and 1567 participants that compared fluphenazine with low-potency antipsychotic drugs. The size of the included studies was between 40 and 438 participants. Overall, sequence generation, allocation procedures and blinding were poorly reported. Fluphenazine was not significantly different from low-potency antipsychotic drugs in terms of response to treatment (fluphenazine 55%, low-potency drug 55%, 2 RCTs, n = 105, RR 1.06 CI 0.75 to 1.50, moderate quality evidence). There was also no significant difference in acceptability of treatment with equivocal numbers of participants leaving the studies early due to any reason (fluphenazine 36%, low-potency antipsychotics 36%, 6 RCTs, n = 1532, RR 1.00 CI 0.88 to 1.14, moderate quality evidence). There was no significant difference between fluphenazine and low-potency antipsychotics for numbers experiencing at least one adverse effect (fluphenazine 70%, low-potency antipsychotics 88%, 1 RCT, n = 65, RR 0.79 CI 0.58 to 1.07, moderate quality evidence). However, at least one movement disorder occurred significantly more frequently in the fluphenazine group (fluphenazine 15%, low-potency antipsychotics 10%, 3 RCTs, n = 971, RR 2.11 CI 1.41 to 3.15, low quality of evidence). In contrast, low-potency antipsychotics produced significantly more sedation (fluphenazine 20%, low-potency antipsychotics 64%, 1 RCT, n = 65, RR 0.31 CI 0.13 to 0.77, high quality evidence). No data were available for the outcomes of death and quality of life. The results of the primary outcome were robust in a number of subgroup and sensitivity analyses.Adverse effects such as akathisia (fluphenazine 15%, low-potency antipsychotics 6%, 5 RCTs, n = 1209, RR 2.28 CI 1.58 to 3.28); dystonia (fluphenazine 5%, low-potency antipsychotics 2%, 4 RCTs, n = 1309, RR 2.66 CI 1.25 to 5.64); loss of associated movement (fluphenazine 20%, low-potency antipsychotics 2%, 1 RCT, n = 338, RR 11.15 CI 3.95 to 31.47); rigor (fluphenazine 27%, low-potency antipsychotics 12%, 2 RCTs, n = 403, RR 2.18 CI 1.20 to 3.97); and tremor (fluphenazine 15%, low-potency antipsychotics 6%, 2 RCTs, n = 403, RR 2.53 CI 1.37 to 4.68) occurred significantly more frequently in the fluphenazine group.For other adverse effects such as dizziness (fluphenazine 8%, low-potency antipsychotics 17%, 4 RCTs, n = 1051, RR 0.49 CI 0.32 to 0.73); drowsiness (fluphenazine 18%, low-potency antipsychotics 25%, 3 RCTs, n = 986, RR 0.67 CI 0.53 to 0.86); dry mouth (fluphenazine 11%, low-potency antipsychotics 18%, 4 RCTs, n = 1051, RR 0.63 CI 0.45 to 0.89); nausea (fluphenazine 4%, low-potency antipsychotics 15%, 3 RCTs, n = 986, RR 0.25 CI 0.14 to 0.45); and vomiting (fluphenazine 3%, low-potency antipsychotics 8%, 3 RCTs, n = 986, RR 0.36 CI 0.18 to 0.72) results favoured fluphenazine with significantly more events occurring in the low-potency antipsychotic group for these outcomes.
  
  
  CONCLUSIONS
  The results do not show a clear difference in efficacy between fluphenazine and low-potency antipsychotics. The number of included studies was low and their quality moderate. Therefore, further studies would be needed to draw firm conclusions about the relative effects of fluphenazine and low-potency antipsychotics.
authors.affiliation: Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Möhlstr. 26, München, Germany, 81675.
authors.forename: Magdolna
authors.initials: M
authors.lastname: Tardy
authors.forename: Maximilian
authors.initials: M
authors.lastname: Huhn
authors.forename: Rolf R
authors.initials: RR
authors.lastname: Engel
authors.forename: Stefan
authors.initials: S
authors.lastname: Leucht
mesh_terms: D017109:Akathisia, Drug-Induced; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D005476:Fluphenazine
references.citation: J Clin Psychiatry. 2011 Mar;72(3):349-55
references.pmid: 21367356
references.citation: Br J Psychiatry. 1964 Jul;110:531-9
references.pmid: 14153363
references.citation: J Nerv Ment Dis. 1968 Aug;147(2):173-83
references.pmid: 5677325
references.citation: Schizophr Res. 2011 Mar;126(1-3):212-9
references.pmid: 21062670
references.citation: Science. 1975 Jun 20;188(4194):1217-9
references.pmid: 1145194
references.citation: Acta Psychiatr Scand Suppl. 1974;249:65-77
references.pmid: 4608707
references.citation: Schizophr Bull. 1983;9(4):528-32
references.pmid: 6140751
references.citation: World J Biol Psychiatry. 2005;6(3):132-91
references.pmid: 16173147
references.citation: Acta Psychiatr Scand Suppl. 1968;203:225-30
references.pmid: 4881876
references.citation: J Health Serv Res Policy. 2000 Jan;5(1):12-6
references.pmid: 10787581
references.citation: Arch Gen Psychiatry. 1971 Nov;25(5):404-9
references.pmid: 4943915
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Can J Psychiatry. 1988 Dec;33(9):816-8
references.pmid: 2905632
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: Therapie. 1999 Jul Aug;54(4):405-11
references.pmid: 10667106
references.citation: Cochrane Database Syst Rev. 2013 Nov 05;(11):CD001949
references.pmid: 24194433
references.citation: Psychopharmacol Bull. 1985;21(3):533-7
references.pmid: 2863848
references.citation: Br J Psychiatry. 2005 Oct;187:366-71
references.pmid: 16199797
references.citation: Am J Psychiatry. 1964 Apr;120:1010-1
references.pmid: 14138834
references.citation: Lancet. 2009 Jan 3;373(9657):31-41
references.pmid: 19058842
references.citation: BMJ. 1997 Sep 6;315(7108):600
references.pmid: 9302962
references.citation: Cochrane Database Syst Rev. 2014 Jul 08;(7):CD009396
references.pmid: 25003310
references.citation: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004964
references.pmid: 15495131
references.citation: N Engl J Med. 1994 Mar 10;330(10):681-90
references.pmid: 8107719
references.citation: Cochrane Database Syst Rev. 2014 Jul 09;(7):CD009268
references.pmid: 25007358
references.citation: Arch Gen Psychiatry. 1978 Feb;35(2):153-5
references.pmid: 623501
references.citation: Am J Psychiatry. 1975 Dec;132(12):1237-45
references.pmid: 914
references.citation: Cochrane Database Syst Rev. 2014 Oct 07;(10):CD009369
references.pmid: 25290157
references.citation: BMJ. 2010 Mar 23;340:c869
references.pmid: 20332511
references.citation: Biol Psychiatry. 2010 Feb 1;67(3):255-62
references.pmid: 19897178
references.citation: Schizophr Res. 2005 Nov 15;79(2-3):231-8
references.pmid: 15982856
references.citation: Int J Epidemiol. 2002 Feb;31(1):140-9
references.pmid: 11914310
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Psychopharmacologia. 1965 Feb 15;7(2):89-106
references.pmid: 5318926
references.citation: BMJ. 1996 Nov 9;313(7066):1200
references.pmid: 8916759
references.citation: Acta Psychiatr Scand. 1973;49(1):65-76
references.pmid: 4572169
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000307
references.pmid: 15674872
references.citation: Cochrane Database Syst Rev. 2014 Sep 01;(9):CD009227
references.pmid: 25177834
references.citation: Arch Gen Psychiatry. 1964 Mar;10:246-61
references.pmid: 14089354
references.citation: Br J Psychiatry. 2000 Mar;176:249-52
references.pmid: 10755072
references.citation: Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
references.pmid: 15000267
references.citation: Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
references.pmid: 15133589
references.citation: Dis Nerv Syst. 1967 Jun;28(6):369-83
references.pmid: 5342391
references.citation: Am J Epidemiol. 1999 May 1;149(9):876-83
references.pmid: 10221325
references.citation: Cochrane Database Syst Rev. 2015 Jan 16;1:CD009831
references.pmid: 25592299
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
references.pmid: 17015810
references.citation: J Gen Intern Med. 1992 Nov-Dec;7(6):623-9
references.pmid: 1453246
references.citation: Arch Gen Psychiatry. 1983 Aug;40(8):893-6
references.pmid: 6347119